Resources from the same session
Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial
Presenter: David Tougeron
Session: Mini Oral Session 2
Resources:
Slides
Webcast
Invited discussant LBA2 and LBA1
Presenter: Shouki Bazarbashi
Session: Mini Oral Session 2
Resources:
Slides
Webcast
LBA2 - Interim analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
Presenter: Francesco Sclafani
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Mini Oral Session 2
Resources:
Webcast
LBA1 - Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial
Presenter: David Tougeron
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Combined analyses of ctDNA and Immunoscore in stage III colon cancer patients: A post hoc analysis of the IDEA-France and -Greece trials
Presenter: Julien Taieb
Session: Mini Oral Session 2
Resources:
Slides
Webcast
Invited discussant LBA2 and LBA1
Presenter: Shouki Bazarbashi
Session: Mini Oral session 2
Resources:
Slides
Webcast
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial
Presenter: Mehraneh Dorna Jafari
Session: Mini Oral Session 2
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session 2
Resources:
Webcast
Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
Presenter: Kristen Ciombor
Session: Mini Oral Session 2
Resources:
Slides
Webcast